Bio-Rad Laboratories, Inc.

330.42-5.70 (-1.7%)

Oct 28, 4:00:02 PM EDT · NYSE · BIO · USD

Upcoming Earnings

Report date

Oct 29, 2025 (today)

Key Stats

Market Cap

8.84B

P/E (TTM)

30.31

Basic EPS (TTM)

10.90

Dividend Yield

Recent Filings

8-K

Co-founder Alice Schwartz passes

9/30/25Sep 30, 2025

Bio-Rad Laboratories announced the passing of co-founder and Director Emeritus Alice N. Schwartz on September 25, 2025, at age 99. Schwartz, who co-founded the company in 1952 with her husband and drove its expansion from specialty chemicals into clinical diagnostics via a pivotal 1960s thyroid test kit, served actively on the board until 2022. Her legacy of scientific passion endures. Bio-Rad generated $2.6 billion in 2024 revenues.

8-K

Bio-Rad unveils ddPCR innovations

8/26/25Aug 26, 2025

Bio-Rad Laboratories hosted a webinar on August 26, 2025, spotlighting its Droplet Digital PCR portfolio as the market innovator since 2010, backed by over 12,000 peer-reviewed publications. The presentation highlights droplet-based technology's superior precision for applications in oncology, biopharma, and biosurveillance, positioning ddPCR to capture growth in the $600M absolute quantitation segment amid evolving needs beyond qPCR and NGS limitations. Bio-Rad's 490,000+ validated assays fuel seamless tech shifts. Forward-looking plans target accelerating customer adoption, yet actual results hinge on market risks.

10-Q

Q2 FY2025 results

7/31/25Jul 31, 2025

Bio-Rad's Q2 sales edged up 2.1% y/y to $651.6M, with Life Science growing 4.9% on process chromatography strength while Clinical Diagnostics held flat amid China reimbursement cuts. Gross margins slipped to 53.0% from 55.6%, pressured by higher material costs and lower absorption, yet operating income fell less sharply to $77.1M from $101.5M. A $334.4M gain on Sartorius holdings flipped the prior year's $2.9B loss, driving net income to $317.8M and $11.67 diluted EPS from a $76.26 loss. Cash from operations hit $246.4M YTD, funding $216.7M for the Stilla acquisition—closed June 30 for $257.9M total (cash/contingent), adding $161.9M goodwill and $94.4M developed technology. Debt stands steady at $1.2B (3.3%/3.7% senior notes due 2027/2032), with $369.3M cash and $200M revolver availability. Free cash flow reached $166.3M YTD (derived). Restructuring costs mounted to $35.6M YTD. Sartorius volatility remains a key risk.

8-K

Bio-Rad Q2 revenue rises 2.1%

7/31/25Jul 31, 2025

Bio-Rad Laboratories reported Q2 2025 revenue of $651.6 million, up 2.1% from $638.5 million last year, driven by 4.9% growth in Life Science from process chromatography and food safety, while Clinical Diagnostics held flat amid China reimbursement cuts. Non-GAAP operating income fell to $88.6 million from $106.9 million, but margins improved via expense controls. The company completed its Stilla Technologies acquisition, bolstering Droplet Digital PCR offerings. It now eyes 0-1% full-year currency-neutral revenue growth and 12-13% non-GAAP operating margins. Volatility in Sartorius investment swings GAAP results wildly.

8-K

Bio-Rad appoints new commercial leader

7/28/25Jul 28, 2025

Bio-Rad Laboratories announced Rajat Mehta's appointment as Executive Vice President, Global Commercial Operations, effective August 4, 2025, succeeding retiring veteran Mike Crowley, who will assist through September. Mehta joins from Labcorp with deep expertise in biopharma and diagnostics, poised to drive Bio-Rad's commercial strategy amid global market challenges. His track record in growth and team-building bolsters execution. Forward-looking statements highlight integration risks.

About

Bio-Rad Laboratories, Inc. manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials, such as cells, proteins, and nucleic acids used in biopharmaceutical manufacturing, quality control process, food safety, and science education applications. It also designs, manufactures, markets, and supports test systems, informatics systems, test kits, and specialized quality controls for hospitals, diagnostic reference, and transfusion and physician office laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.

CEO

Mr. Norman D. Schwartz

IPO

2/27/1980

Website

https://www.bio-rad.com

Employees

7,700

Sector

Healthcare

Industry

Medical Devices